Paeds · nephrology-urology-fluids-and-electrolytes
Chronic kidney disease and progression
Also known as CKD · Chronic renal failure · Chronic renal insufficiency · Kidney failure progression · CKD-MBD
Fellowship guide to chronic kidney disease and its progression in children: the KDIGO definition (kidney abnormalities or low GFR for over three months), the GFR G1 to G5 and albuminuria A1 to A3 staging grid that drives risk and referral, why congenital CAKUT dominates paediatric causes, the hyperfiltration vicious cycle that makes CKD self-amplifying, the nephroprotective bundle of blood-pressure control below the 50th percentile with ACE inhibitors or ARBs, and the longitudinal management of growth failure, anaemia, acidosis and mineral-bone disease that lets a child reach transplantation in the best possible condition.
On this page
Study tools
Your progress
Saved on this device.
Practise this topic
Target exams
Red flags
- A child whose growth crosses centile lines downward while carrying a known kidney abnormality
- Rising creatinine with new or worsening hypertension and proteinuria signalling accelerated progression
- Unexplained anaemia, metabolic acidosis or failure to thrive that is revealed to be chronic kidney disease
- Hyperkalaemia, fluid overload or uraemic symptoms in advanced CKD threatening acute decompensation
- Severe secondary hyperparathyroidism or hyperphosphataemia driving mineral-bone disease and vascular risk
- Late presentation of bilateral cystic or dysplastic kidneys with eGFR already in the kidney-failure range
Life stages
Care settings
Clinical exam formats
Board mappings
- Defines chronic kidney disease and applies the KDIGO GFR and albuminuria staging grid
- Recognises growth failure, hypertension and anaemia as presenting features of CKD in children
- Initiates nephroprotective care with blood-pressure control and early nephrology referral
- Explains the hyperfiltration vicious cycle and the evidence for ACE inhibitor or ARB therapy to slow progression
- Justifies blood-pressure targets below the 50th percentile and interprets ambulatory blood-pressure monitoring
- Coordinates longitudinal management of growth, anaemia, acidosis and mineral-bone disease toward transplantation
- KDIGO definition and G1 to G5, A1 to A3 staging of chronic kidney disease
- Common paediatric causes including CAKUT and the principle of progression
- Nephroprotective bundle and when to escalate to a specialist centre
- Long-case assessment of a child with established CKD including growth, blood pressure and complications
- Counselling families on prognosis, dialysis versus transplantation and transition to adult care
- Recognising and managing acute decompensation of chronic kidney disease
- Level 1: Recognises CKD as kidney abnormalities present for over three months and identifies high-risk presentations
- Level 2: Applies KDIGO staging and initiates nephroprotection with blood-pressure and proteinuria control
- Level 3: Leads the multidisciplinary management of complications and preparation for kidney replacement therapy
- KDIGO GFR categories G1 to G5 and albuminuria categories A1 to A3
- Bedside Schwartz formula for estimating GFR in children
- Mechanism of CKD progression and the role of renin-angiotensin system blockade
- Assessment of growth, blood pressure and fluid status in a child with CKD
- Interpretation of anaemia, acidosis and mineral-bone markers across CKD stages
- Structured explanation of the management ladder from nephroprotection to transplantation
- Definition and staging of chronic kidney disease in children using KDIGO criteria
- Identification and initial management of progression risk factors
- Recognition and treatment of CKD complications including anaemia and mineral-bone disorder
- Defines CKD and distinguishes it from acute kidney injury
- Initiates nephroprotective therapy and timely nephrology referral
- Monitors growth, blood pressure and complications across the CKD trajectory
- Canadian approach to CKD classification and the GFR and albuminuria grid
- Blood-pressure targets and renin-angiotensin blockade in paediatric CKD
- Coordination of transition from paediatric to adult nephrology services
Overview & Definition
A boy born with posterior urethral valves is now seven. His creatinine has crept up over years, his height has fallen from the 50th to the 9th centile, and his blood pressure is above the 95th centile. He has chronic kidney disease: the slow, lasting loss of the kidney's ability to filter blood and maintain balance, present for more than three months and carrying consequences for health. The time frame matters — it separates CKD from the recoverable acute kidney injury that happens over days, and the health consequence matters, because a slightly low filtering rate without any damage marker or any impact is not yet disease. [1]
KDIGO, the international body that sets kidney-disease standards, defines chronic kidney disease as either a glomerular filtration rate below 60 mL per minute per 1.73 square metres for over three months, or markers of kidney damage present for over three months. The damage markers are albuminuria, an abnormal urine sediment, persistent electrolyte and acid-base disturbance from tubular disease, structural abnormalities found on imaging, a history of kidney transplantation, or a cystic or inherited kidney disease. In children the emphasis falls differently from adults: congenital and structural problems dominate, and the kidney is still expected to support a growing body, so even moderate loss of function can derail growth and development. [1]
References12ShowHide
- [1]Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int, 2024.PMID 38490803
- [2]Levin A, Ahmed SB, Carrero JJ, Foster B, et al Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknowns. Kidney Int, 2024.PMID 38519239
- [3]Wühl E, Trivelli A, Picca S, et al. Strict blood-pressure control and progression of renal failure in children. N Engl J Med, 2009.PMID 19846849
- [4]Schwartz GJ, Muñoz A, Schneider MF, Mak RH, et al New equations to estimate GFR in children with CKD. J Am Soc Nephrol, 2009.PMID 19158356
- [5]Hogg RJ, Furth S, Lemley KV, Portman R, et al National Kidney Foundation's Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification. Pediatrics, 2003.PMID 12777562
- [6]Wong CJ, Moxey-Mims M, Jerry-Fluker J, Warady BA, et al CKiD (CKD in children) prospective cohort study: a review of current findings. Am J Kidney Dis, 2012.PMID 23022429
- [7]Schaefer B, Wühl E Educational paper: Progression in chronic kidney disease and prevention strategies. Eur J Pediatr, 2012.PMID 22968936
- [8]Fadrowski JJ, Pierce CB, Cole SR, Moxey-Mims M, et al Hemoglobin decline in children with chronic kidney disease: baseline results from the chronic kidney disease in children prospective cohort study. Clin J Am Soc Nephrol, 2008.PMID 18235140
- [9]Gerson AC, Butler R, Moxey-Mims M, Wentz A, et al Neurocognitive outcomes in children with chronic kidney disease: current findings and contemporary endeavors. Ment Retard Dev Disabil Res Rev, 2006.PMID 17061289
- [10]Drube J, Wan M, Bonthuis M, Wühl E, et al Clinical practice recommendations for growth hormone treatment in children with chronic kidney disease. Nat Rev Nephrol, 2019.PMID 31197263
- [11]Shroff R, Aitkenhead H, Costa N, Trivelli A, et al Normal 25-Hydroxyvitamin D levels are associated with less proteinuria and attenuate renal failure progression in children with CKD. J Am Soc Nephrol, 2016.PMID 26069294
- [12]Shroff R, Wan M, Nagler EV, Bakkaloglu S, et al Clinical practice recommendations for treatment with active vitamin D analogues in children with chronic kidney disease Stages 2-5 and on dialysis. Nephrol Dial Transplant, 2017.PMID 28873971